ArticleWorld journal of urology2026
Predictive factors for negative prostate biopsy in PI-RADS 5 patients: a multivariate analysis of clinical and imaging-based factors.
Article in World journal of urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeMultiparametric MRI (mpMRI) is crucial for diagnosing prostate cancer, with PI-RADS 5 lesions indicating a high likelihood of clinically significant prostate cancer (csPCa). However, some patients with PI-RADS 5 lesions have negative biopsies, and optimal management remains unclear. This study aims to identify clinical and imaging factors predicting negative biopsy outcomes in these cases.
methodsWe conducted a retrospective analysis of a prospectively maintained single-center cohort of patients with PI-RADS 5 lesions who underwent transrectal cognitive fusion-guided prostate biopsy between November 2016 and December 2024. All procedures included systematic 12-core sampling plus targeted biopsies of mpMRI-detected lesions. Clinical and imaging variables-including age, PSA, PSA density, DRE, prostate volume, prior negative biopsy, lesion location, and TRUS findings-were evaluated as potential predictors of negative biopsy outcomes using univariate and multivariate logistic regression, and ROC curve analysis.
resultsA study of 990 patients with PI-RADS 5 lesions found that 113 (11.4%) had negative biopsies. Among the 863 diagnosed with prostate cancer, 92.8% (801) had csPCa. Independent predictors of negative biopsy included prostate volume > 60 cc (22.3%), normal DRE (20.0%), prior negative biopsy (27.9%), transition zone (TZ) lesion location (25.8%), and absence of a suspicious hypoechoic lesion on TRUS (19.9%). The likelihood of a negative biopsy increased with the combination of these factors-rising to 64.3% when all were present. Multivariate analysis confirmed these as independent predictors, with their combination enhancing predictive accuracy (AUC ≥ 0.84).
conclusionDespite the high probability of clinically significant prostate cancer in PI-RADS 5 lesions, approximately 10-12% of cases result in negative biopsy findings. Our results indicate that combining prostate volume, lesion location, DRE findings, and TRUS characteristics allows for improved risk stratification. These predictive factors can improve both pre- and post-biopsy decision-making by helping tailor follow-up strategies such as repeat biopsy, mpMRI monitoring, or PSA testing to each individual patient.
Indexed as
Identifiers
41543542What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.